Monitoring for cytomegalovirus and Epstein-Barr virus infection in chronic lymphocytic leukemia patients receiving i.v. fludarabine-cyclophosphamide combination and alemtuzumab as consolidation therapy
暂无分享,去创建一个
[1] F. Baldanti,et al. Monitoring human cytomegalovirus infection in transplant recipients. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[2] T Hamblin,et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial , 2007, The Lancet.
[3] M. Grever,et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Hallek,et al. Due to low infection rates no routine anti‐infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine‐based first line therapy , 2007, British journal of haematology.
[5] M. Keating,et al. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. , 2006, Clinical lymphoma & myeloma.
[6] J. Gribben,et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] G. Brittinger,et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. , 2005, Blood.
[8] P. Ueland,et al. Automated assay for the determination of methylmalonic acid, total homocysteine, and related amino acids in human serum or plasma by means of methylchloroformate derivatization and gas chromatography-mass spectrometry. , 2005, Clinical chemistry.
[9] D. Catovsky,et al. Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis. , 2005, Leukemia research.
[10] R. Gräsbeck,et al. Hereditary juvenile cobalamin deficiency caused by mutations in the intrinsic factor gene. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[11] Ashley P Ng,et al. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. , 2005, Haematologica.
[12] E. Nexo,et al. Nonradioactive Vitamin B 12 Absorption Test Evaluated in Controls and in Patients with Inherited Malabsorption of Vitamin B 12 , 2005 .
[13] E. Nexo,et al. Holo-transcobalamin concentration and transcobalamin saturation reflect recent vitamin B12 absorption better than does serum vitamin B12. , 2004, Clinical chemistry.
[14] A. Chapelle,et al. Genetically heterogeneous selective intestinal malabsorption of vitamin B12: Founder effects, consanguinity, and high clinical awareness explain aggregations in Scandinavia and the Middle East , 2004, Human mutation.
[15] S. Barutça,et al. Oral versus intramuscular cobalamin treatment in megaloblastic anemia: a single-center, prospective, randomized, open-label study. , 2003, Clinical therapeutics.
[16] A. Ho,et al. Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia , 2003, British journal of haematology.
[17] F. Baldanti,et al. The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders , 1999, British journal of haematology.
[18] J. Ritz,et al. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling , 1999, Nature Medicine.
[19] R. Allen,et al. Effective treatment of cobalamin deficiency with oral cobalamin. , 1998, Blood.
[20] G. Schilirò,et al. Efficacy of oral administration of high-dose cobamamide in a patient with Imerslund-Gräsbeck syndrome. , 1996, Pediatric hematology and oncology.
[21] E. Podell,et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. , 1988, The New England journal of medicine.
[22] R. Berlin,et al. Oral treatment of pernicious anemia with high doses of vitamin B12 without intrinsic factor. , 2009, Acta medica Scandinavica.